Evidence that remote MoCA administration is valid for those with cerebellar ataxia may make testing more accessible than ever before. https://t.co/Bac1ejnc9w
LSVT stands for Lee Silverman Voice Therapy. It is a speech therapy program that is well researched and widely used in speech pathology for treating dysarthria (slurred or unclear speech) in Parkinson Disease. https://t.co/xbDQtHWSsq
Could other brain cells besides neurons or nerve cells play an important role in spinocerebellar ataxia type 7 (SCA7)? A new study offers an important clue by looking beyond neurons and focusing on the brain's support cells called astrocytes. https://t.co/Iou4EBt6ED
Before a new drug or therapy can reach patients, researchers and regulatory agencies need evidence that it is safe and effective. One of the most reliable ways to gather this evidence is through a randomized controlled trial (RCT). https://t.co/bvkqKzeNkQ
How the gut helps clean the brain: New evidence supports the importance of gut health and sleep management for people with neurodegenerative disorders. https://t.co/KHmy9tVnHB
The functional Scale for the Assessment and Rating of Ataxia (f-SARA) is a streamlined clinical tool used to measure disease progression in ataxia. https://t.co/Wq60oYZtEb
Tiny tags, big impact: new research reveals chemical tags on ataxin-3 protein influences its behavior and may contribute to brain cell death in SCA3. https://t.co/0D8DmudJ6e
The Hauser Lab at the German Center for Neurodegenerative Diseases studies how genetic changes damage brain cells and lead to neurodegenerative diseases like Ataxia. https://t.co/nZE4T9Eb0M
Endpoints are clearly defined outcomes that are measured during a trial to help determine the effects of an intervention. Clinical trials usually include several types of endpoints, each serving a different purpose. https://t.co/oUQ34h9meA
Levacetylleucine, sold under the brand name Aqneursa, is an FDA-approved treatment for Niemann-Pick disease type C. Levacetylleucine is also in Phase III clinical trial for Ataxia-Telangiectasia and is being studied for the treatment of other diseases. https://t.co/q6ZuI8b7p7
Ever wonder if experiences early in life impact symptoms of a genetic disease? Researchers found that genetics isn’t the only thing to consider in SCA6. https://t.co/duN1hHkV9A
Expanded access (sometimes called “compassionate use” or “pre-approval access”) is a way for patients to access medical products before they are approved for a particular condition. https://t.co/sfipbxWfXf
New mouse studies show that mutant ataxin-2 causes dramatically more damage in older animals, revealing aging as an independent driver of disease severity. https://t.co/6TgEh2iuld
Walking tests in a hospital is not the same as walking at home. Wearable sensors show that real-world walking is more variable than in the hospital. https://t.co/gMUTSIdPPM
New clues into SCA1: RNA gets trapped inside toxic ataxin-1 clumps in brain cells, disrupting the production of proteins and contributing to disease. https://t.co/vUvEPspuoX
¿Te sientes cansado(a)? No estás solo(a). La fatiga es un síntoma común de las ataxias espinocerebelosas y afecta la calidad de vida. https://t.co/MlL3mX2pAg